Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$480.60 USD

480.60
547,954

+4.78 (1.00%)

Updated May 3, 2024 04:00 PM ET

After-Market: $480.68 +0.08 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Masimo (MASI) Q4 Earnings Beat Estimates, View Impressive

by Zacks Equity Research

Masimo (MASI) sees expansion in gross and operating margin in Q4.

Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Amedisys' (AMED) fourth-quarter earnings benefit from solid year-over-year growth in Medicare and non-Medicare revenues within Home Health.

Ecolab (ECL) Earnings and Revenues Miss Estimates in Q4

by Zacks Equity Research

Strength in the Global Industrial arm drives Ecolab's (ECL) Q4 results.

Change Healthcare (CHNG) Q3 Earnings Top Estimates, Down Y/Y

by Zacks Equity Research

Change Healthcare's (CHNG) third-quarter fiscal earnings benefit from solid performance across the segments - Software and Analytics and Network Solutions. However, decline in revenues remains a woe.

DexCom (DXCM) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter earnings benefit from higher revenues and solid performing Sensor and Transmitter segments.

AMN Healthcare (AMN) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

AMN Healthcare's (AMN) Q4 results gain from core Nurse and Allied Solutions units.

Luminex (LMNX) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

Luminex's (LMNX) fourth-quarter earnings benefit from higher revenues and solid performance across System Sales, Service and Other Revenues. However, gross margin contraction remains a woe.

DaVita (DVA) Earnings Beat Estimates in Q4, Revenues Miss

by Zacks Equity Research

DaVita (DVA) gains from dialysis services in the United States in Q4.

Has IDEXX Laboratories (IDXX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (IDXX) Outperforming Other Medical Stocks This Year?

Cardinal Health (CAH) Q2 Earnings & Revenues Top Estimates

by Zacks Equity Research

Cardinal Health (CAH) fiscal second-quarter results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.

Becton, Dickinson (BDX) Q1 Earnings Beat, Revenues Rise Y/Y

by Zacks Equity Research

Becton, Dickinson (BDX) sees softness in BD Medical unit, slashes FY20 view.

ABIOMED (ABMD) Earnings Beat Estimates in Q3, Revenues Miss

by Zacks Equity Research

Flagship Impella drives ABIOMED's (ABMD) fiscal third-quarter results; FY20 revenue guidance slashed.

Here's Why You Should Retain IDEXX Laboratories Stock Now

by Zacks Equity Research

Investor confidence remains high in IDEXX (IDXX) stock, thanks to solid prospects.

IDEXX (IDXX) Q4 Earnings Top Estimates, Revenues Grow Y/Y

by Zacks Equity Research

The year-over-year upside in IDEXX's (IDXX) revenues was primarily driven by strong global gains in CAG Diagnostics' recurring revenues.

Idexx Laboratories (IDXX) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Idexx (IDXX) delivered earnings and revenue surprises of 14.29% and 0.92%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Idexx Laboratories (IDXX) Q4 Earnings Expected to Decline

by Zacks Equity Research

Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for IDEXX Laboratories' (IDXX) Q4 Earnings?

by Zacks Equity Research

IDEXX's (IDXX) is likely to report strong earnings for Q4, courtesy of a global surge in CAG Diagnostic revenues.

IDEXX Launches Cytology Service to Upgrade Veterinary Care

by Zacks Equity Research

IDEXX (IDXX) upgrades veterinary care experience by launching a rapid digital cytology service, thus enabling the provision of faster results.

Sanghamitra Saha headshot

S&P 500 Up 1000 Points in a Month: 10 Stocks Boosted the ETF

by Sanghamitra Saha

The S&P 500 touched the 3,300 mark on Jan 16, having added 1000 points in less than a month. Which stocks led to the ETF rally.

Sanghamitra Saha headshot

Top-Ranked Nasdaq-100 ETF at New High: 5 Best Stocks

by Sanghamitra Saha

Likelihood of a soon-to-be-signed U.S.-China trade deal, upbeat holiday season sales expectations and decent earnings have led the Nasdaq-100 ETF to a new high.

IDEXX (IDXX) Tops Q3 Earnings Estimates, Lowers EPS View

by Zacks Equity Research

IDEXX (IDXX) impresses investors with solid third-quarter 2019 results on robust performance across all business segments.

Idexx Laboratories (IDXX) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Idexx (IDXX) delivered earnings and revenue surprises of 9.73% and 1.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Impressive Near-Term Outlook for Medical Instruments Industry

by Urmimala Biswas

Growing medical awareness and economic prosperity enhance the uptake of medical instruments in the emerging economies.

Urmimala Biswas headshot

Medical Instruments' Oct 31 Earnings Roster: IDXX, ABMD & More

by Urmimala Biswas

Earnings and revenues for the Medical Instruments sector in the third quarter are likely to have declined sequentially. Read to know how a few companies from the sector might have fared in the period.

Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.